AzTrials
AzTrials

Macular HolesMACROHOLENCT06433284

Comparative Study of Decellularized Human Amniotic Membrane Hydrogel and Inverted Internal Limiting Membrane Flap in Idiopathic Large Macular Holes

A study testing 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade and 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade in people with Macular Holes, run by Walailak University at 1 site in Thailand.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The human amniotic membrane (hAM) patch, introduced by Rizzo et al. in 2018, showed a 100% anatomical success rate for large or failed macular holes over a 6-month follow-up. Despite its regenerative properties like promoting angiogenesis and having low immunogenicity, its clinical use is limited by challenges such as… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Macular Holes
What is being tested?
25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade and 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
26 participants
Where
1 siteThailand
Study dates
1 Oct 2024to 30 Jan 2027
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years Idiopathic full-thickness macular hole with minimum diameter >400 µm confirmed on SD-OCT Willing and able to provide written informed consent and comply with 6-month follow-up schedule

Who cannot join

  • Full-thickness macular hole with minimum diameter >1,500 µm Traumatic macular holes Myopic macular holes (axial length >26.5 mm or refractive error less than -8.0 diopters) Co-existing ocular pathologies independently affecting visual acuity (glaucoma with visual field loss, advanced age-related macular degeneration, diabetic macular edema, or epiretinal membrane requiring surgery) Active intraocular inflammation or infection Previous vitreoretinal surgery Medical unfitness for local anesthesia surgery as determined by the anesthesiologist Inability to maintain prone positioning postoperatively

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Jakkrit Juhong, MD. contact

+66816773406

jakkrit.ju@wu.ac.th

Thailand1 site, 1 recruiting
  • Jakkrit Juhong

    Nakhon Si Thammarat, Thasala, 80160

    Jakkrit Juhong, MD, +66816773406, jakkrit.ju@wu.ac.th

    Jakkrit Juhong, MD

    Recruiting

Other trials in Thailand

About this study

Official title: Comparative Study of Decellularized Human Amniotic Membrane Hydrogel and Inverted Internal Limiting Membrane Flap in Idiopathic Large Macular Holes (MACROHOLE): a Randomized-control Trial

The human amniotic membrane (hAM) patch, introduced by Rizzo et al. in 2018, showed a 100% anatomical success rate for large or failed macular holes over a 6-month follow-up. Despite its regenerative properties like promoting angiogenesis and having low immunogenicity, its clinical use is limited by challenges such as trimming to fit small holes and complications during insertion. To overcome these issues, decellularized amniotic membrane (dAM) has been processed into a hydrogel form, enhancing its applicability and allowing it to be used as an injectable hydrogel for minimally invasive therapies. While dAM hydrogels have been used in various medical fields, their application in intraocular surgery is new. This study proposes using dAM hydrogel for large macular hole closure, comparing its effectiveness to the inverted ILM flap technique in a randomized controlled trial.

Read the detailed description

A macular hole (MH) is a neuroepithelial defect in the macular area of the retina. The estimation of macular hole incidence about 33 of every 10,000 person in individuals older than 55 years old1. The female-to-male ratio is 2 to 3:1. Idiopathic macular hole (IMH) is MHs occurring independently of primary ocular diseases such as trauma and vitreoretinopathy2 and represents the predominant subtype of MH, constituting approximately 83%1. There is a 5% to 15% risk of developing macular hole in the other eye if a macular hole develops in one eye.1 In 1988, Gass proposed a classification system for idiopathic macular holes, as well as a new hypothesis for its pathogenesis, which emphasizes the role of the vitreo-macular tangential traction in the formation of macular holes3. Macular hole closure can occurred spontaneously in approximately 5-10% cases in early stages. Pars plana vitrectomy with internal limiting membrane (ILM) peeling and gas tamponade has been the standard of care of small size macular hole treatment with success rate more than 90%4. However, in large macular hole more than 400 um, the success rate is lower. Previous study showed closure rate of large macular hole > 400 μm is 56% with poor visual outcome.4,5 Several new techniques have been described to improve anatomical and functional outcomes in cases of large macular holes by inserting alternative tissues into the macular hole, such as the ILM flap, human amniotic membrane patch6, or retinal tissue implantation, to promote anatomical closure and improve visual acuity. The utilization of ILM flap coverage has emerged as an effective surgical approach for treating large, full-thickness idiopathic MH and myopic MH. This technique was initially introduced in 1999, showing promising results in enhancing macular hole closure rates through ILM peeling. Several subsequent studies 7-9 have further substantiated the efficacy of ILM flap coverage, making it the standard surgical treatment for large macular hole cases. However, this technique is often hindered by limitations related to the technical complexity of surgery and the risk of retinal trauma.

The human amniotic membrane (hAM) patch, proposed by Rizzo et al. in 20186, serves as another alternative technique for large or failed macular hole cases. The anatomical success rate was 100% during the 6 months follow-up. The exceptional biological properties of hAM, including its promote angiogenesis10, low immunogenicity11, and anti-inflammatory11,12, anti-fibrotic13, and antibacterial characteristics14, make it highly suitable for regenerative medicine and intraocular implantation. However, the clinical application of thin hAM sheets is limited by several challenges, such as the difficulty of trimming it to fit very small hole sizes (< 0.2 cm), tissue loss after insertion into the PPV port, and complications during the insertion of the hAM patch into the hole. To address these limitations, processing decellularized amniotic membrane (dAM) tissue into a hydrogel form has enhanced its processability and applicability15. This transformation allows it to be used as an injectable hydrogel for minimally invasive therapies and facilitates its manipulation into the macular hole.

dAM hydrogels have been applied in various fields, including skin repair, cardiac treatment, cartilage regeneration, endometrial regeneration, vascular grafts, dental pulp regeneration, and as cell culture/carrier platforms. However, their use in intraocular surgery has not yet been established. Additionally, the benefits of dAM hydrogel over hAM tissue include lower immunogenicity due to the decellularization process since the resident cells may cause intense host immunologic reactions after transplantation and transplant rejection and the homogeneous distribution of biochemical substances within the hydrogel structure.15 In this study, we will be the first to propose a new technique and invention for closing large macular holes using human amniotic membrane hydrogel filling in the hole after standard ILM peeling. We conducted a randomized controlled trial to compare the anatomical and visual outcomes of the inverted ILM flap technique (IFT) with the dAM hydrogel technique in idiopathic large macular holes with a minimum diameter (MD) greater than 400 μm.

In vitro biological characterization of dAM hydrogel, including RPE-1 retinal pigment epithelial cell viability (CCK-8 assay at 24 and 48 hours) and scaffold-guided cell migration (transwell invasion assay), is performed at the Department of Physiology, Faculty of Medical Science, Naresuan University, as part of batch quality control prior to clinical use. Batch release requires RPE-1 cell surface viability at 48 hours to be not significantly different from Matrigel reference scaffold (one-way ANOVA, p = ns), consistent with active cell migration into the three-dimensional scaffold rather than cytotoxicity. This study is conducted under IRB approval No. WUEC-24-331-01 (Amendment No. 1, effective 1 May 2025).

Conditions
Macular Holes
Being tested
25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade, 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade
Keywords
macular holes, decellularized amniotic membrane, human amniotic membrane hydrogel, vitrectomy, inverted ILM flap, randomized controlled trial
Medical subject headings
Retinal Perforations

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponadeProcedure or surgery

    Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. "Flower petal" type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole

  • 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponadeProcedure or surgery

    Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining then filling the hole with amniotic membrane hydrogel and sulfur hexafluoride (SF6) tamponade

Study groups in NCT06433284
Study groupRoleWhat they receive
Inverted flapActive comparatorPatients who will undergo 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade.
Receives: Procedure: 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade
Amniotic membrane hydrogelExperimentalPatients who will undergo 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling, amniotic membrane hydrogel filling and SF6 tamponade.
Receives: Procedure: 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Closure rate

    Type 1 anatomical closure rate at 6 months postoperatively, defined per the Gigante et al. classification as complete flattening of the macular hole with neurosensory retina fully covering the retinal pigment epithelium across the fovea on SD-OCT, assessed by a masked investigator on anonymized images.

    Measured: 6 months

Secondary outcomes (4)
  1. Best corrected visual acuity (BCVA)

    Change in best-corrected visual acuity (BCVA) from baseline to 6 months postoperatively, measured in logMAR by a masked assessor, comparing dAM hydrogel instillation versus inverted ILM flap technique.

    Measured: 6 months

  2. EZ and ELM integrity

    Ellipsoid zone (EZ) integrity grade (Continuous/Discontinuous/Absent) and external limiting membrane (ELM) continuity (Continuous/Discontinuous) at 6 months postoperatively on SD-OCT, graded by a masked investigator on anonymized images.

    Measured: 6 months

  3. Intraocular pressure (IOP)

    Change in intraocular pressure (IOP) from baseline to 6 months postoperatively, measured by Goldmann applanation tonometry.

    Measured: 6 months

  4. Intraoperative and postoperative complications

    Incidence of intraoperative and postoperative complications including intraocular inflammation (graded by SUN criteria), endophthalmitis, retinal detachment, elevated IOP requiring treatment, and cataract progression requiring surgery.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 May 2024
  2. Study start1 Oct 2024
  3. Primary completion30 Aug 2026 (estimated)
  4. Study completion30 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
26 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06433284
Sponsor's protocol ID
WU999
Acronym
MACROHOLE
Status last verified
Sep 2026
First submitted
22 May 2024
Last updated
9 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Michalewska Z, Michalewski J, Adelman RA, Nawrocki J. Inverted internal limiting membrane flap technique for large macular holes. Ophthalmology. 2010 Oct;117(10):2018-25. doi: 10.1016/j.ophtha.2010.02.011. Epub 2010 Jun 11.

    PubMed 20541263
  • Juhong J, Impheng H, Sukhang M, Mordmuang A. First-in-human application of decellularized human amniotic membrane hydrogel as an injectable intraocular scaffold for large idiopathic full-thickness macular hole closure: four-month clinical outcomes. Int J Retina Vitreous. 2026 Jun 24. doi: 10.1186/s40942-026-00893-4. Online ahead of print.

    PubMed 42343490

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in